HEMAB
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
HEMAB
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2017-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.hemab.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Nginx Sitelinks Search Box Organization Schema
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Castle Creek Biosciences
Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
Placentum
Placentum is dedicated to the development of novel antioxidant formulations.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Sorriso Pharmaceuticals
Sorriso Pharmaceuticals is a biotech firm developing disease-modifying antibodies for the treatment of inflammatory diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Founder
Investors List
RA Capital Management
RA Capital Management investment in Series A - Hemab
Novo Holdings
Novo Holdings investment in Series A - Hemab
HealthCap
HealthCap investment in Series A - Hemab
Novo Holdings
Novo Holdings investment in Seed Round - Hemab
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-21 | Hemab Appoints Mads Behrndt as Chief Financial Officer |
Official Site Inspections
http://www.hemab.com Semrush global rank: 5.9 M Semrush visits lastest month: 1.4 K
- Host name: 198.202.211.1
- IP address: 198.202.211.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Hemab"
Hemab - bleeding disorder company
Our strategic guidance, Hemab 1-2-5 TM is targeting development of five clinical assets by 2025 to transform treatment for these rare disorders and enable patients everywhere to live healthy, …See details»
Hemab - Crunchbase Company Profile & Funding
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, …See details»
Hemab Therapeutics - LinkedIn
At Hemab, we may not be the biggest research organization in this industry, but we've been involved with 60% of all approved drugs in this space. Our deeply experienced team of drug …See details»
All News - Hemab
COPENHAGEN, DENMARK AND CAMBRIDGE, MASS., US – January 13, 2025 – Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic …See details»
Novo Holdings Creates New Rare Bleeding Disorder …
Dec 14, 2020 Hemab was co-founded by Johan Faber and Søren Bjørn, who until 2018, held leadership positions within hemophilia drug research and …See details»
Hemab - Leadership Team - The Org
The Leadership Team at Hemab Therapeutics is responsible for driving the company's strategic vision and operational direction in the development of innovative treatments for rare bleeding …See details»
Hemab Therapeutics Expands Management Team with …
Jan 13, 2025 Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today …See details»
Hemab Therapeutics Expands Management Team with …
Jan 13, 2025 About Hemab Therapeutics Hemab is a clinical-stage biotech company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. …See details»
Hemab Therapeutics Announces First Patient Dosed in ... - Markets …
Jan 10, 2023 Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia PRESS RELEASE PR Newswire …See details»
Hemab raises $55M to target multiple rare bleeding …
Jul 22, 2021 Hemab has raised $55 million to advance a pipeline of bispecific and monoclonal antibodies to treat patients with rare bleeding disorders. The series A round equips Hemab to take its lead program ...See details»
Novo Holdings co-leads Hemab’s US$ 55M Series A to …
Jul 22, 2021 Copenhagen, Denmark and Boston, US – 22 July 2021 – Novo Holdings, a leading international life science investor, today announces that it has co-led alongside HealthCap and RA Capital Management a US$ 55M Series …See details»
Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 …
Jan 10, 2023 The company is continuing to advance its strategic guidance, Hemab 1-2-5 ™, to develop five clinical assets by 2025 to transform treatment for rare bleeding and thrombotic …See details»
Hemab - Raised $1.93B Funding from 9 investors - Tracxn
Mar 6, 2025 Hemab has raised a total funding of $1.93B over 3 rounds from 9 investors. Investors include Novo Holdings, RA Capital Management and 7 others. Their latest funding …See details»
Hemab Therapeutics | Cambridge MA - Facebook
Hemab partners with patients, HCPs, advocacy organizations, and scientists to raise awareness of rare bleeding disorders. Page · Biotechnology Company 101 Main Street, Cambridge, MA, …See details»
Hemab Therapeutics Announces Start of Velora Pioneer, a Phase …
Feb 27, 2025 The company's strategic guidance, Hemab 1-2-5 TM, targets building a pipeline of multiple development programs to deliver long-awaited innovation for patients with high unmet …See details»
Director, Drug Substance Development, CMC | Hemab
Hemab is driven by a vision to grow into a leading commercial biotech company, and we seek individuals who are passionate about contributing to this transformative journey. ... and plays a …See details»
Hemab Therapeutics Announces First Patient Dosed in Phase 1/
Jan 10, 2023 Facilitated in collaboration with the UK-based clinical research organization Richmond Pharmacology, the trial is expected to expand into the US and other EU countries. …See details»
Hemab Therapeutics Presents Interim Data from Ongoing
Feb 7, 2025 Hemab is a clinical-stage biotech company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, …See details»
Working at Hemab - Glassdoor
Glassdoor gives you an inside look at what it's like to work at Hemab, including salaries, reviews, office photos and more. This is the Hemab company profile. All content is posted anonymously …See details»
成立仅两年！Hemab融资1.9亿美元，聚焦出血和血栓疾病疗法开 …
⌈ByDrug医药新闻摘要⌋ 2023-02-22 15:13，触界生物：Hemab成立于2020年12月，在丹麦和美国设置双总部，专注于研发抗体药物治疗罕见的出血疾病，成立仅两年，公司已完成累计1.9亿 …See details»